|
 |
Portfolio Companies In the News: 2008
| October 8, 2008
|
FDA Clears Neurostar® TMS Therapy for
the Treatment of Depression
|
| October 7, 2008
|
Neotropix® Announces Expansion of On-going Clinical Trial
for Adult Neuroendocrine Cancers
|
| October 6, 2008
|
Biolex Therapeutics Completes $60 Million Series D Financing to
Accelerate Development of Locteron® in Hepatitis C
|
| October 6, 2008
|
Biolex Therapeutics Enters Into Agreement to Acquire Full
Locteron® Commercial Rights
|
| August 1, 2008
|
EKR Therapeutics Receives Approval for
Ready-to-Use Intravenous Bags of Cardene® I.V.
|
| June 17, 2008
|
Tranzyme
Pharma’s Ghrelin Agonist TZP-102 Demonstrates Safety and High Oral Bioavailability in the
Successful Completion of a Phase I Trial
|
| June 12, 2008
|
Transave Announces Positive Phase II Results for Once-daily
Arikace™ in the Treatment of Cystic Fibrosis Patients who ave
Pseudomonas Lung Infections
|
| June 3, 2008
|
Protez Pharmaceuticals to be Acquired by Novartis for up to $400 million in cash
|
| April 1, 2008
|
Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
|
| March 31, 2008
|
Study Confirms Anti-infective
Arikace™ Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing
Cystic Fibrosis Patients.
|
| March 31, 2008
|
Transave, Inc. Raises $35 Million Through Series D Convertible
Preferred Stock Financing
|
| March 10, 2008
|
Philly VCs back Jersey drug seller EKR
|
| March 10, 2008
|
Argolyn Bioscience Grows Management Team
|
| March 10, 2008
|
EKR Therapeutics Raises Over $145 Million in Support of Growth
|
| February 27, 2008
|
Tengion Appoints Jeff Randall to Board of Directors
|
| February 12, 2008
|
Nitric BioTherapeutics Hires Joel Lippman, M.D. as GM of Its Antimicrobial Business
|
| January 29, 2008
|
Tranzyme Pharma Receives IND Clearance for Its Oral Ghrelin Agonist, TZP-102, for the Treatment of Gastroparesis
|
| January 11, 2008
|
Nucleonics Initiates Hepatitis B Clinical Trial with Expressed Interfering RNA Therapeutic
|
| January 3, 2008
|
Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
|
Portfolio Companies In the News: 2007
| December 10, 2007
|
Biolex Researchers Present Results of Anti-CD20 Antibody with Optimized Glycosylation at ASH Conference
|
| December 7, 2007
|
Philadelphia Inquirer: Protez CEO, Christopher Cashman, Honored at the Eastern Technology Council's Enterprise Awards
|
| November 16, 2007
|
Discovery Labs' Response to Surfaxin Approvable Letter Deemed Complete by FDA
|
| November 8, 2007
|
Amicus Therapeutics and Shire plc enter into $440 million ex-US Licensing Agreement to Develop and Commercialize Amigal™, Plicera™ and AT2220
|
| November 7, 2007
|
Tengion: The Gray Sheet - Paving a Path to a Regenerative Medicine Industry.
|
| November 1, 2007
|
Tranzyme Pharma Closes New $20 Million Financing
|
| November 1, 2007
|
Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin® for RDS in Premature Infants
|
| October 30, 2007
|
Neotropix: Virus Shows Some Cancer-Killing Abilities
|
| October 24, 2007
|
Tranzyme Pharma’s Motilin Antagonist TZP-201 Shows Potential for Preventing and Treating Chemotherapy-Induced Diarrhea (CID)
|
| October 23, 2007
|
Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
|
| October 22, 2007
|
EKR Therapeutics Secures Credit Facility; Company Well Positioned to Strategically Pursue Product Acquisitions to Fuel Long-Term Growth Momentum
|
| October 15, 2007
|
Tengion Closes $33 Million in Series C Funding
|
| October 9, 2007
|
Optherion, Inc. Completes $37 Million Start Up Financing
|
| October 1, 2007
|
Surfaxin® Process Validation Batches Achieve Stability Milestone to Enable Filing of Response to FDA Approvable Letter
|
| September 17, 2007
|
Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
|
| August 15, 2007
|
EKR Therapeutics Raises Over $13 Million in a Series C Financing Round From New and Existing Investors
|
| August 15, 2007
|
EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur®, a Novel Extended-Release Opioid Analgesic for Post Operative Pain
|
| August 14, 2007
|
Biolex Files for Initial Public Offering
|
| July 26, 2007
|
Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial with its Novel Ghrelin Agonist, TZP-101, for Post-Operative Ileus
|
| July 13, 2007
|
Biolex Therapeutics Presents Preclinical Results for Clot Buster BLX-155 at the International Society on Thrombosis and Haemostasis Meeting
|
| July 12, 2007
|
Tranzyme Pharma Receives FDA Fast Track Designation for its Novel Ghrelin Agonist, TZP-101, for the Treatment of Severe Gastroparesis
|
| June 25, 2007
|
Argolyn Bioscience Raises $15.8 Million Round of Financing
|
| June 08, 2007
|
Nupathe Reports Postive Phase one Results for NP101 Transdermal Therapy for Acute Migraine
|
| June 07, 2007
|
Medmark Co-Founder Shines
|
| June 04, 2007
|
Celator Pharmaceuticals® Study Shows Anti-Tumor Activity in Cancer
Patients Treated with Therapy Based on Ratiometric Dosing
|
| June 01, 2007
|
Pharmaceutical Commerce: Making Medicine Personal
|
| May 31, 2007
|
Amicus Therapeutics Announces Pricing of Initial Public Offering of 5,000,000 Shares of Common Stock
|
| May 24, 2007
|
Biolex Therapeutics Raises $30 Million to Advance its Hepatitis C Drug Candidate and Other Pipeline Programs
|
| May 21, 2007
|
NeuroStar TMS Therapy Improved Quality of Life in Patients with Major Depression in Clinical Trials
|
| May 09, 2007
|
Discovery’s KL-4 Surfactant Technology Demonstrates Novel Anti-inflammatory Properties
|
| May 08, 2007
|
Discovery Labs Presents Surfaxin® and Aerosurf™ Data at the Pediatric Academic Societies Annual Meeting
|
| May 02, 2007
|
Nucleonics Receives FDA Clearance to Begin Phase 1 Trial of Expressed RNAi Approach to Treating Chronic Hepatitis B Infections
|
| March 30, 2007
|
Amicus Therapeutics Files for Initial Public Offering
|
| March 27, 2007
|
Regado Biosciences Completes $23 Million Series C Financing
|
| March 21, 2007
|
Amicus Therapeutics Presents Positive Results from Phase 1 Clinical Studies of Plicera™ for Gaucher Disease
|
| March 19, 2007
|
Amicus Therapeutics Presents Data from Preclinical and Phase 1 Studies of Amigal™ for Fabry Disease.
|
| March 1, 2007
|
Biolex Therapeutics Researchers Present Preclinical Data for Direct-acting Thrombolytic BLX-155 at Scientific Conference
|
| February 8, 2007
|
Transport Delivers Unprecedented Levels of Acyclovir with Novel Five Percent Gel Formulation
|
| February 1, 2007
|
USPTO Rejects All Claims in Re-exam of Benetic’s Patent in Response to Nucleonics’ request for Re-examination
|
| February 1, 2007
|
Pfizer to Acquire Biorexis to Access Novel Technology Platform and Early Stage Diabetes Pipeline.
|
| January 5, 2007
|
Tengion Launches First Phase II Clinical Trial of Regenerated Human Organ
|
Portfolio Companies In the News: 2006
| December 13, 2006
|
Tranzyme Pharma Announces Issuance of European Patent Protecting Company’s Novel Macrocyclic Chemistry
|
| November 28, 2006
|
Biolex Announces Publication in Nature Biotechnology
|
| September 20, 2006
|
Studies Published in PNAS on the Mechanism of Amicus' Experimental Treatment for Gaucher Disease
|
| September 14, 2006
|
BioWorld Today: Neurology Firm NuPathe Gets $15M For Lead Migraine Patch
|
| June 29, 2006
|
LLR Partners and Quaker Bioventures Announce Sale of Portfolio Company Medmark Holdings Inc.
|
| June 26, 2006
|
Tengion Inc. Completes $50 Million Series "B" Round
|
| June 19, 2006
|
BioWorld Today: Mining Minds Of Doctors For Better Predicting Drug Market
|
| June 12, 2006
|
Tetralogic Pharmaceuticals Completes $36 Million Series B Financing
|
| May 18, 2006
|
Pittsburgh Tribune-Review: Company gets $20M in venture capital
|
| May 17, 2006
|
Philadelphia Business Journal: Quaker BioVentures-backed Company Planning IPO
|
| May 17, 2006
|
Neotropix Receives FDA Approval to Begin Clinical Trials With First Investigational Cancer Drug
|
| May 01, 2006
|
Managed Healthcare Executive: Specialty pharmacy find its way in determining efficiencies
|
| April 18, 2006
|
The Philadelphia Inquirer: Berwyn biotech firm to be sold
|
| April 12, 2006
|
The Daily Deal: Theranox pipes in $14M
|
| April 11, 2006
|
Venture Wire Professional: Theranox To Help Heal Wounds With $14M Series A
|
| April 11, 2006
|
Biolex Therapeutics Announces Expansion of Medarex Collaboration
|
| April 10, 2006
|
Theranox Raises $14m to Develop Gaseous Nitric Oxide for the Treatment of Chronic Wounds
|
| March 20, 2006
|
TargetRx Unveils First Industry Analysis Linking Pharmaceutical Sales Force Effectiveness with Physician Prescribing
|
| February 22, 2006
|
BioWorld Today: Precision’s Series B Adds $20M For Cancer Regimen
|
| February 21, 2006
|
Precision Therapeutics lands $20 million in venture capital funding
|
| February 17, 2006
|
Pittsburgh Business Times: Precision Therapeutics lands $20 million in venture capital funding
|
| February 15, 2006
|
Amicus Therapeutics’ AT2101 Granted Orphan Drug Designation for the Treatment of Gaucher Disease
|
| January 10, 2006
|
Tranzyme Pharma Receives IND Clearance for its Novel Ghrelin Agonist, TZP-101
|
Portfolio Companies In the News: 2005
| November 16, 2005
|
Biolex Therapeutics Announces Recruitment of Three Key Management Team Additions to Accelerate Commercialization of Lead Programs
|
| November 2, 2005
|
Biolex Therapeutics Announces Initiation of Phase 1 Clinical Study of Hepatitis C Candidate Locteron™
|
| October 25, 2005
|
The Star Ledger: Ventures find Jersey generous
|
| October 13, 2005
|
Stanley B. Blaylock Appointed ceo of Medmark Inc.
|
| October 05, 2005
|
CFO: Venture Capital Not-So-Easy Money
|
| September 23, 2005
|
Philadelphia Business Journal: Amicus Therapeutics banks $55M to forward its drug research
|
| September 23, 2005
|
Philadelphia Business Journal: Data-mining efforts expand
|
| September 21, 2005
|
Neotropix Announces Progress in Research Program
|
| September 8, 2005
|
Amicus Therapeutics Raises $55 Million Series C Financing
|
| September 2, 2005
|
Triangle Business Journal: Duckweed science showing promise, Biolex raises $36M
|
| September 1, 2005 |
Biolex Therapeutics Raises $36 Million in Venture Financing
|
| August 25, 2005
|
Philadelphia Inquirer: Protez Raises $15 Million in Venture Capital
|
| August 24, 2005
|
Protez Pharmaceuticals Closes $15 Million Financing to Progress Lead Antibiotic Compound
|
| August 12, 2005
|
Regado Bioscience Completes $20 Million Series B Financing
|
| July 14, 2005
|
Immune Control Raises $11.3 Million to Commence Two Clinical Trials
|
|
July 14, 2005
|
Philadelphia Inquirer: Former Penn scientist finds... Biotech is in his blood
|
| May 13, 2005
|
Triangle Business Journal: Tranzyme Nails $26M in VC to Speed Up Drug
|
| May 13, 2005
|
Tranzyme Pharma Completes $32 Million Financing
|
|
May 13, 2005
|
BioWorld Today: Tranzyme’s story: Early Stage Firm Brings in $32M Financing
|
|
May 4, 2005
|
The Star-Ledger: State finds biotech to fund
|
|
May 4, 2005
|
BioWorld Today: Combo-chemo approach nets $40M in VC money for Celator
|
|
May 3, 2005
|
Celator Pharmaceuticals Closes $40M Financing
|
|
April 22, 2005
|
Philadelphia Business Journal: TargetRx database analyses reasons behind prescriptions
|
|
April 22, 2005
|
TargetRx Announces $15 Million in Funding Led by Quaker BioVentures
|
| April 19, 2005 |
Thymitaq Completes Enrollment in Pivotal Phase III Liver Cancer Study
|
| April 4, 2005 |
Discovery Labs' Surfaxin (lucinactant) Phase 3 Results Published in Pediatrics, the Official Journal of the American Academy of Pediatrics
|
| March 23, 2005
|
Transport and Nexus Announce Expansion Of The Board And Management Teams Through The Addition Of Key Personnel
|
| March 21, 2005
|
Biolex forms Bond Strategic Alliance with Centocor to Develop and Manufacture Therapeutic Proteins
|
|
March 21, 2005
|
Philadelphia Inquirer: A mighty mote called BioRexis
|
| March 9, 2005
|
Nucleonics Reports Granting of Two Key Patents on RNA Interference by Australian Patent Office
|
| February 25, 2005
|
Discovery Labs Announces Completion of $29.1 Million Registered Direct Offering
|
| February 14, 2005
|
Discovery Labs Receives Approvable Letter from FDA for Surfaxin for Respiratory Distress Syndrome in Premature Infants
|
|
February 10, 2005
|
Philadelphia Inquirer: Eximias names a new president
|
| February 9, 2005
|
Eximias Pharmaceutical Corporation Appoints New CEO
|
| January 27, 2005
|
Transport Announces Agreement with GlaxoSmithKline for European Rights to a Device/Drug Combination System for High-Potency Delivery of Acyclovir
|
|
January 14, 2005
|
Philadelphia Business Journal: Newcomer Neotropix explores viral therapies for cancer
|
|
January 9, 2005
|
Daily Local News: Turning viruses into virotherapy
|
| January 6, 2005
|
Biolex submits IND and CTA for BLX-883, a Form of Alfa Interferon Manufactured with the Biolex Lex System
|
Portfolio Companies In the News: 2004
| December 13, 2004
|
Neotropix Attracts $10 Million Series A Round For Development of Novel Virotherapies to Treat Cancer
|
| November 22, 2004
|
Transport Pharmaceuticals Secures $27 Million in Venture Financing to Continue Development of Unique Drug Delivery Platform
|
| November 17, 2004
|
Nucleonics Licenses Key Apath Technology for Use in Hepatitis C Therapeutic
|
| November 15, 2004
|
Discovery Laboratories added to NASDAQ Biotech Index
|
| October 13, 2004
|
Nucleonics Secures $2.7M Equipment Financing Facility
|
| September 29, 2004
|
W. Thomas Amick Joins BioRexis Board of Directors
|
| July 29, 2004
|
BioRexis Appoints Michael Celano, CPA, as Vice President, Finance and Chief Financial Officer
|
| July 28, 2004
|
Eximias Named Among Top 15 Emerging Biotech Companies of 2004
|
| June 30, 2004
|
Discovery Laboratories Elevated to NASDAQ National Market
|
| June 17, 2004
|
Biolex Receives CED's 2004 Deal of the Year Award
|
|
June 4, 2004
|
Pittsburgh Business-Times: Man on the Move
|
| June 1, 2004
|
Nucleonics Adds Additional $8.3 Million to Series B Financing, Bringing Total Raised Thie Round to $49.2 Million
|
|
June 1, 2004
|
Specialty Pharmacy News: Private Equity Firms Infuse Medmark with $28M in New Capital
|
|
May 10, 2004
|
Buyouts: LLR Partners, Quaker Carve Out Medmark
|
| May 6, 2004
|
Biolex Acquires Epicyte Pharmaceutical
|
|
April 29, 2004
|
Pittsburgh Post-Gazette: Medical firms gets big boost
|
|
April 29, 2004
|
LLR Partners and Quaker BioVentures Continue Investment Momentum with $28M Equity Investment in Medmark
|
| April 13, 2004
|
BioRexis Appoints Vanaja V. Ragazan, MD, Vice President, Clinical and Regulatory Affairs
|
| March 31, 2004 |
Eximias Pharmaceutical Corporation Announces $63.5 Million Private Placement
|
| March 16, 2004
|
Curcell and Neotropix Enter PER.C6 Licensing Agreement in the Field of Viral Therapy
|
| March 11, 2004
|
BioRexis Completes $30 Million Series B Financing
|
Portfolio Companies In the News: 2003
|
|
